Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00221312 · ClinicalTrials.gov registry record
Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 48
- Enrollment target
NCT00221312: Completed study, sponsored by University of California, San Francisco.
NCT00221312 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00221312 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
Study Summary
This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition). During the three to five years prior to the menopause, the rate of bone loss increases. One way that physicians treat this is with oral contraceptive medication. However, the incidence of complications from oral contraceptives after the age of 40 increases. Therefore, a non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a class of compounds called bisphosphonates. This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.
Interventions
- DRUG Fosamax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2002-05 |
| Est. Completion | 2007-07 |
What the finished NCT00221312 record still lists
NCT00221312 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Fosamax is the first listed.
NCT00221312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00221312 about?
NCT00221312 is a clinical study titled "Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss". This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years ...
What is the current status of trial NCT00221312?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2002-05. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00221312?
The interventions under investigation include: Fosamax (DRUG).
Who is sponsoring clinical trial NCT00221312?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia